Edwards Lifesciences Corp (EW) has a current Price-to-Book (P/B) ratio of 4.86. Compared to its 3-year average P/B ratio of 6.09, the current P/B ratio is approximately -20.32% higher. Relative to its 5-year average P/B ratio of 8.22, the current P/B ratio is about -40.94% higher. Edwards Lifesciences Corp (EW) has a Forward Free Cash Flow (FCF) yield of approximately 1.62%. Compared to its 3-year average FCF yield of 1.33%, the current FCF yield is approximately 22.49% lower. Relative to its 5-year average FCF yield of 1.56%, the current FCF yield is about 4.38% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for EW competitors is 4.98, providing a benchmark for relative valuation. Edwards Lifesciences Corp Corp (EW.N) exhibits a P/S ratio of 7.65, which is 53.61% above the industry average. Given its robust revenue growth of 13.26%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of EW increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of EW in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is EW currently overvalued or undervalued?

What is Edwards Lifesciences Corp (EW) fair value?

EW's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Edwards Lifesciences Corp (EW) is between 75.46 to 106.74 according to relative valuation method.

How does EW's valuation metrics compare to the industry average?

The average P/S ratio for EW's competitors is 4.98, providing a benchmark for relative valuation. Edwards Lifesciences Corp Corp (EW) exhibits a P/S ratio of 7.65, which is 53.61% above the industry average. Given its robust revenue growth of 13.26%, this premium appears unsustainable.

What is the current P/B ratio for Edwards Lifesciences Corp (EW) as of Mar 02 2026?

As of Mar 02 2026, Edwards Lifesciences Corp (EW) has a P/B ratio of 4.86. This indicates that the market values EW at 4.86 times its book value.

What is the current FCF Yield for Edwards Lifesciences Corp (EW) as of Mar 02 2026?

As of Mar 02 2026, Edwards Lifesciences Corp (EW) has a FCF Yield of 1.62%. This means that for every dollar of Edwards Lifesciences Corp's market capitalization, the company generates 1.62 cents in free cash flow.

What is the current Forward P/E ratio for Edwards Lifesciences Corp (EW) as of Mar 02 2026?

As of Mar 02 2026, Edwards Lifesciences Corp (EW) has a Forward P/E ratio of 30.98. This means the market is willing to pay $30.98 for every dollar of Edwards Lifesciences Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Edwards Lifesciences Corp (EW) as of Mar 02 2026?

As of Mar 02 2026, Edwards Lifesciences Corp (EW) has a Forward P/S ratio of 7.65. This means the market is valuing EW at $7.65 for every dollar of expected revenue over the next 12 months.

EW Valuation